Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Tetanus Toxoid × Lymphoid × Clear all
NCT00369291 2017-11-29

CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
19 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Germ Cell and Embryonal, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡